Rana Chanchal, Babu Suresh, Agarwal Harshita, Singhai Atin, Kumar Madhu, Singh Vishwajeet, Sinha R J, Shankhwar S N
Department of Pathology, King George's Medical University, Lucknow, Uttar Pradesh India.
Department of Urology, King George's Medical University, Lucknow, Uttar Pradesh India.
Indian J Surg Oncol. 2021 Dec;12(4):678-685. doi: 10.1007/s13193-021-01394-6. Epub 2021 Aug 18.
GATA , , has now been demonstrated as a valuable and sensitive marker for conventional urothelial carcinoma with sparse literature related to its expression in various histological variants. It is a prospective study where 74 consecutive cases of bladder carcinoma were included between August 2016 and January 2017 followed by immunohistochemistry to assess GATA 3 expression in conventional as well as different urothelial carcinoma (UC) variants. Overall, 57 of the 74 lesions (77%) demonstrated nuclear staining for GATA 3. GATA 3 expression significantly correlated with histological grade ( < 0.001) and muscle invasion ( = 0.005). Divergent differentiation was observed in 54% (40/74) of the total cases. The study included 12 different variants of urothelial carcinoma. All or majority of the cases of clear cell (6/6, 100%), glandular (6/8, 75%), and sarcomatoid (4/6, 66.7%) variants expressed GATA 3 in a moderate to strong fashion and belonged to group III or IV. Nested variant, small cell carcinoma, pure squamous cell carcinoma, and squamous component of urothelial carcinoma with squamous differentiation do not show any GATA 3 expression. GATA 3 was expressed more intensely as well as in greater number of tumor cells at lymph node metastatic tumor deposits as compared to the primary tumor. GATA 3 expression was not significantly associated with tumor stage or patients' clinical outcomes. GATA 3 is expressed in majority of variants of UC albeit with variable staining; however, situation is challenging in some variants known to be associated with poor prognosis like nested variant, small cell carcinoma, and squamous cell carcinoma where it is not expressed. Hence, the sensitivity of this determinant is diminished in these variants, which may affect the interpretation of GATA 3 stains at metastatic sites as well as their distinction from secondary bladder involvement, by tumors of non-urothelial origin.
GATA 3现已被证明是传统尿路上皮癌的一种有价值且敏感的标志物,但关于其在各种组织学变体中表达的文献较少。这是一项前瞻性研究,2016年8月至2017年1月期间纳入了74例连续的膀胱癌病例,随后进行免疫组织化学以评估GATA 3在传统以及不同尿路上皮癌(UC)变体中的表达。总体而言,74个病变中有57个(77%)显示GATA 3核染色。GATA 3表达与组织学分级(P<0.001)和肌肉浸润(P=0.005)显著相关。在54%(40/74)的病例中观察到不同分化。该研究包括12种不同的尿路上皮癌变体。透明细胞变体(6/6,100%)、腺性变体(6/8,75%)和肉瘤样变体(4/6,66.7%)的所有或大多数病例以中度至强的方式表达GATA 3,属于III组或IV组。巢状变体、小细胞癌、纯鳞状细胞癌以及具有鳞状分化的尿路上皮癌的鳞状成分均未显示任何GATA 3表达。与原发性肿瘤相比,GATA 3在淋巴结转移瘤灶中表达更强烈,且在更多肿瘤细胞中表达。GATA 3表达与肿瘤分期或患者临床结局无显著相关性。尽管染色情况各异,但GATA 3在大多数UC变体中表达;然而,在一些已知预后不良的变体中情况具有挑战性,如巢状变体、小细胞癌和鳞状细胞癌,这些变体中不表达GATA 3。因此,在这些变体中该决定因素的敏感性降低,这可能会影响转移部位GATA 3染色的解读以及它们与非尿路上皮起源肿瘤引起的继发性膀胱受累的区分。